SG11202106582YA - Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 - Google Patents

Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Info

Publication number
SG11202106582YA
SG11202106582YA SG11202106582YA SG11202106582YA SG11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA SG 11202106582Y A SG11202106582Y A SG 11202106582YA
Authority
SG
Singapore
Prior art keywords
alkylene
independently selected
alkyl
membered heterocycloalkyl
cycloalkyl
Prior art date
Application number
SG11202106582YA
Other languages
English (en)
Inventor
Jun Pan
Jeremy Roach
Song Mei
Chunhong He
Liangxing Wu
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG11202106582YA publication Critical patent/SG11202106582YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202106582YA 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 SG11202106582YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US201962935891P 2019-11-15 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Publications (1)

Publication Number Publication Date
SG11202106582YA true SG11202106582YA (en) 2021-07-29

Family

ID=69467674

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106582YA SG11202106582YA (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Country Status (20)

Country Link
US (3) US11459329B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898627A1 (cg-RX-API-DMAC7.html)
JP (2) JP7414827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210116488A (cg-RX-API-DMAC7.html)
CN (2) CN114787160B (cg-RX-API-DMAC7.html)
AU (1) AU2019401649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011948A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210336A (cg-RX-API-DMAC7.html)
EC (1) ECSP21044843A (cg-RX-API-DMAC7.html)
IL (2) IL318278A (cg-RX-API-DMAC7.html)
MA (1) MA54551A (cg-RX-API-DMAC7.html)
MX (1) MX2021007426A (cg-RX-API-DMAC7.html)
PE (1) PE20220277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106582YA (cg-RX-API-DMAC7.html)
TW (2) TW202504901A (cg-RX-API-DMAC7.html)
WO (1) WO2020132197A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414827B2 (ja) * 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11840546B2 (en) * 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
KR102961396B1 (ko) 2022-11-28 2026-05-08 계명대학교 산학협력단 신규한 pim 키나아제 억제제 및 이의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
DE602005023763D1 (de) 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101150581B1 (ko) * 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
EA201000615A1 (ru) * 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド 肝臓の増殖を増大させる方法
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
MX2015005375A (es) 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3500571T3 (pl) 2016-08-17 2021-06-28 Children's Hospital Medical Center Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US11371744B2 (en) 2016-09-15 2022-06-28 Awi Licensing Llc Ceiling system with air movement
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US11840546B2 (en) 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof

Also Published As

Publication number Publication date
JP2022514650A (ja) 2022-02-14
JP2024045155A (ja) 2024-04-02
TWI852968B (zh) 2024-08-21
CR20210336A (es) 2021-12-06
CN120208959A (zh) 2025-06-27
TW202039502A (zh) 2020-11-01
IL284139A (en) 2021-08-31
PE20220277A1 (es) 2022-02-25
JP7723068B2 (ja) 2025-08-13
AU2019401649B2 (en) 2025-08-28
CN114787160A (zh) 2022-07-22
AU2019401649A1 (en) 2021-07-08
MX2021007426A (es) 2021-09-08
CO2021008117A2 (es) 2021-09-20
EP3898627A1 (en) 2021-10-27
CA3124088A1 (en) 2020-06-25
CL2021001656A1 (es) 2021-12-17
US11459329B2 (en) 2022-10-04
IL284139B1 (en) 2025-02-01
US20240309008A1 (en) 2024-09-19
ECSP21044843A (es) 2021-09-30
JP7414827B2 (ja) 2024-01-16
US20200199131A1 (en) 2020-06-25
MA54551A (fr) 2021-10-27
US20220315595A1 (en) 2022-10-06
PH12021551446A1 (en) 2021-12-06
BR112021011948A2 (pt) 2021-09-08
TW202504901A (zh) 2025-02-01
US12030889B2 (en) 2024-07-09
IL318278A (en) 2025-03-01
WO2020132197A1 (en) 2020-06-25
KR20210116488A (ko) 2021-09-27
IL284139B2 (en) 2025-06-01
CN114787160B (zh) 2025-03-25

Similar Documents

Publication Publication Date Title
ZA202005341B (en) Inhibitors of activin receptor-like kinase
ZA202000561B (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
IL261625B (en) Inhibitors of menin-mll in bridged cycles and methods of use
ZA202005666B (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
IL268030A (en) Bicyclics as allosteric shp2 inhibitors
SMT202200326T1 (it) Composti imidazo[4,5-d]pirrolo[2,3-b]piridinici come inibitori di chinasi janus
IL255444B (en) Tricyclic compounds and their uses as phosphodiesterase inhibitors
EP3268004A4 (en) Pyrrolopyridazine inhibitors of irak4 activity
EP3268006A4 (en) Pyrrolotriazine inhibitors of irak4 activity
PL3597649T3 (pl) Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
IL265233A (en) Inhibitors in the SIPO cycles of MENIN-MLL interaction
IL256352A (en) Preparations and methods for inhibiting arginase activity
SG11202005264PA (en) Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
IL267671A (en) Pyrazolopyrimidine compounds and methods of their use
SI3177623T1 (sl) Spojine 6,7-dihidropirazolo(1,5-a)pirazin-4(5H)-on in njihova uporaba kot negativni alosterični modulatorji receptorja MGLU2
IL247948B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL276312B1 (en) Use of Alkoxypyrazoles as nitrification inhibitors
SI3174883T1 (sl) Spojine 6,7-dihidropirazolo(1,5-a)pirazin-4(5H)-on in njihova uporaba, kot negativni alosterični modulatorji receptorjev MGLU2
IL290482A (en) Salt and crystal forms of the activin receptor-like kinase inhibitor
EP3907225A4 (en) COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
EP3313852A4 (en) Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
EP3183256A4 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
PL3826983T3 (pl) Zastosowanie podstawionych 2-tiazolin jako inhibitorów nitryfikacji
MA46176A (fr) Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci